← Back to Search

Dietary Supplement

beta-hydroxy beta-methylbutyrate for Chronic Kidney Disease

N/A
Waitlist Available
Led By Kenneth Wilund, PhD
Research Sponsored by University of Illinois at Urbana-Champaign
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

The purpose of this study is to examine the effect of 6 months of daily beta-hydroxy beta-methylbutyrate (HMB) supplementation on the physical function and the health of bones, arteries and heart in hemodialysis patients.

Eligible Conditions
  • Dialysis Complication
  • Chronic Kidney Disease
  • Muscle Atrophy
  • Kidney Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in lean mass over 6 months
Secondary study objectives
Change in physical function over 6 months

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: beta-hydroxy beta-methylbutyrateExperimental Treatment1 Intervention
Calcium-HMB (3g) will be consumed daily for 6 months by all participants assigned to the HMB group.
Group II: PlaceboPlacebo Group1 Intervention
The placebo group will consume non-nutritive placebo pills daily for 6 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HMB
2016
N/A
~200

Find a Location

Who is running the clinical trial?

University of Illinois at Urbana-ChampaignLead Sponsor
198 Previous Clinical Trials
38,474 Total Patients Enrolled
Kenneth Wilund, PhDPrincipal InvestigatorKinesiology & Community Health, UIUC
3 Previous Clinical Trials
54 Total Patients Enrolled
~3 spots leftby Nov 2025